Meeting Homepage
Sponsors
Registrants Only Area
Speaker Bios
Meeting Committee
Welcome
Registration:
Registration Info
Register
Hotel Reservations
Meeting Program:
Schedule-at-a-Glance
Add-on Seminars
Plenary Sessions
Mini-Plenary Sessions
Workshops-at-a-Glance
Workshops by Track
Workshops
PDS Workshops
CLE
Leadership Forum
Additional Events:
Networking Events
Tech Fair
Tours and Sports
Accompanying Persons Schedule
Power Networking
Sponsorship:
Meeting Sponsors
Sponsorship Opportunities
Power Networking
Sponsorship Opportunities [PDF]
Tech Fair:
Exhibitor Information
Floor Plan [PDF]
Space Application [PDF]
Poster Application [PDF]
Misc. Info:
Weather and Dress
Transportation
Discount Disney Tickets Speakers Only:
Information
|
Speaker Biographies
Al Altomari
Al Altomari has more than 25 years of experience in the pharmaceutical industry, with more than 18 of those years focused on the development and marketing of specialty pharmaceutical products.
Appointed Chief Executive Officer of Barrier Therapeutics in April 2008 and a member of the Company's Board of Directors in January 2008; Al Altomari recently completed the successful sale of Barrier Therapeutics, Inc. (NASDAQ: BTRX) to Stiefel Laboratories for a 73% premium. Al was appointed Chief Commercial Officer of Barrier in August 2003 and later served as Barrier's Chief Operating Officer as of February 2006. During his tenure at Barrier, Al spearheaded the development of Barrier's commercial infrastructure, commercialization of Barrier's product portfolio, as well as management of all worldwide business development initiatives.
Prior to joining Barrier, Al served in numerous executive roles in general management, business development, finance and product launch preparation within Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of the Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Al also served as Vice President of Ortho-McNeil Pharmaceutical's Women's Health Care Franchise where he introduced several life cycle and new product development initiatives, including the launch of ORTHO EVRA™, the contraceptive patch.
Al currently serves as a member of the Board of Directors of Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) and Agile Therapeutics, Inc, a privately held women's health company. In July 2007, Al was recognized by PharmaVoice Magazine as one of the Top 100 Most Inspirational and Influential Leaders in the Life Sciences Industry. He received a Masters in Business Administration from Rider University in Lawrenceville, New Jersey. He completed his undergraduate studies at Drexel University in Philadelphia, Pennsylvania, earning a Bachelors of Science degree with a dual major in finance and accounting. Al currently serves on the Le Bow College (Drexel's Business School) advisory board.
[back to top]
Ronald A. Andrews, Jr.
Ronald A. Andrews, Jr. has been Chief Executive Officer since July 2004. From August 2002, Andrews was Senior Vice President Global Marketing and Commercial Business Development at Pleasanton, CA-based Roche Molecular Diagnostics. In that role, he developed and led the strategic execution for all diagnostic commercial operations. This included the oversight of five Business Sector Vice Presidents responsible for all aspects of global marketing and business development in the areas of blood screening, virology, women's health, microbiology and automation/emerging diagnostics.
Andrews was also responsible for executive direction of all marketing functions, directed the development of the 10-year Strategic Plan for the organization, and completed the reorganization of commercial operations during that period.
From 2000 to 2002 Andrews held two senior executive positions with Indianapolis-based Roche Diagnostics Corporation. As Vice President, U.S. Commercial Operations, Molecular Diagnostics, he directed sales, marketing, technical field support, and product development activities and was responsible for US commercial strategy development for the clinical laboratory market.
Prior to that, as Vice President, Marketing, US Commercial Operations, he was responsible for planning and directing all aspects of the Roche US Laboratory Systems Commercial Operations Marketing which included the clinical chemistry, immunochemistry, hematology, near patient testing and molecular markets.
From 1995 to 2000 Andrews was Vice President of Atlanta Based Immucor, Inc where he helped lead the transition of that company from a reagent manufacturer to an instrument systems company. Prior to Immucor, he spent almost 10 years in management positions of increasing responsibility at Chicago-based Abbott Diagnostics, culminating in the position of Senior Marketing Manager, Business Unit Operations.
Andrews earned a Bachelor's degree in Biology and Chemistry from Spartanburg, SC-based Wofford College in 1981 and has participated extensively in the executive development programs at both Roche and Abbott Labs.
He currently lives with his wife and three children in Danville, California.
[back to top]
Anjan Aralihalli
Anjan Aralihalli, MBA is a Director Business Development/US licensing at sanofi-aventis
where he supports the in-licensing of late-stage and commercial products for
the US commercial organization. Anjan or “AJ” has
over 15 years of experience in the CRO, biopharma and pharmaceutical industries
with varying roles of increasing responsibility ranging from clinical study
management, sales, marketing, corporate finance, business development and strategic
planning. AJ holds an MBA from Queen 's University and earned his
B.Sc. in Exercise Science from Concordia University.
[back to top]
Christopher M. Arena
Chris is currently a partner in the Atlanta office of Woodcock Washburn, a national intellectual property law firm. He is the former Chief Intellectual Property Counsel at Cingular Wireless where he was responsible for all aspects of intellectual property. Prior to that, he was Chief Patent Counsel at BellSouth Corporation and a founding officer of the BellSouth Intellectual Property Group of companies. Before becoming an attorney, he spent eight years as systems engineer and engineering manager for IBM Corporation in Manassas, Va.
This extensive and varied background, including his eleven years as an in-house attorney, has given Chris broad and somewhat unique expertise in all areas of IP law and business. He has particular skill in transactional matters, especially asset acquisition, management and licensing transactions. His focus is on the business implications of intellectual property, where he applies his skills to help clients achieve greater value for their businesses through strategic use of intellectual property.
Chris is the co-author of The Business of Intellectual Property (Oxford University Press, 2008). He holds a bachelor's degree in electrical engineering from the University of Notre Dame and a law degree from George Mason University. He is admitted to practice law in Georgia and Pennsylvania as well as before the U.S. Patent and Trademark Office.
[back to top]
Richard Baker, CLP
Richard Baker, CLP, is the Director of Intellectual Property Licensing for 3Com Corporation. Since joining 3Com, Mr. Baker has been involved in a number of licensing projects and in the management of existing licenses for 3Com.
Rich Baker is also running for a seat in the United States House of Representatives for the Massachusetts 6th Congressional District (North of Boston).
Prior to joining 3Com, Mr. Baker was the Director of Intellectual Property at Schneider Automation. Mr. Baker is an inventor on 15 patents in the Web, embedded Ethernet, and business method areas for his work at Schneider.
Mr. Baker 's graduate studies include Intellectual Property at Franklin Pierce Law Center and Computer Science at Harvard University. He holds a bachelor 's degree in Computer Science and English as a dual major at the University of New Hampshire.
Mr. Baker resides with his wife and son in West Newbury, Massachusetts.
[back to top]
Scott Bearby
Scott Bearby joined the National Collegiate Athletic Association (NCAA) as in-house counsel in 1999 and has served as associate general counsel/managing director of legal affairs since December 2001. Bearby works primarily with NCAA contractual and rights issues, including broadcast/media, marketing, licensing and promotional rights, and championship-related agreements, including those related to the Men 's and Women 's Division I Basketball Championships. He also serves as counsel on intellectual property matters. Bearby serves on the NCAA 's crisis assessment team. In addition, he provides counsel to the NCAA 's family of limited liability companies, including the NIT LLC, the College Football Officiating, LLC, and the Eligibility Center, LLC.
Prior to joining the NCAA, Bearby was in private practice. He holds a law degree from Indiana University Bloomington (1992) and his undergraduate degree from the University of Notre Dame (1988).
Bearby is an adjunct professional of law at Indiana University School of Law in Indianapolis teaching Sports Law, among his other speaking and publishing accomplishments.
[back to top]
Scott Bechtel
Scott Bechtel has over 25 years of experience in high technology product development
and commercialization, including patent portfolio management. His career
has included technical, marketing, and management positions with AT&T,
RCA, TRW, and Maxtek/Tektronix. Scott has helped found three successful
start-ups and managed a business incubator including 7 early stage technology
companies. He has also held key IP management positions with Competitive Technologies
(University Patents) and TAEUS. Scott is author of a popular engineering
textbook on Optoelectronics and holds 4 US patents. He is a Hawk Award and
Eagle Award winner for Department of Defense Program Management and an Eagle
Scout. His bachelor 's degree is in physics with additional coursework
in biology and electrical engineering, and he holds a Masters of Science in
Industrial Administration with Distinction from Carnegie Mellon University.
[back to top]
Louis P. Berneman
Louis P. Berneman is President of Texelerate, LLC, a business development consultancy.
Through Texelerate, Lou is
- President, TMune Therapeutics, Inc, developing T-cell adoptive imunotherapies;
- Partner, Osage University Partners, a development-stage venture fund; and
- Consultant, Paul Capital Partners, a royalty monetization fund.
From 1995-2005, Lou was Managing Director of the Center for Technology Transfer
(CTT) at the University of Pennsylvania. From 1989-1995, Berneman was Director,
Licensing and Business Development at Virginia 's Center for Innovative Technology.
From 1984-1989, he founded and served as a Director, President and CEO of
Biotherapeutics, Inc., a provider of cancer biotherapy services. In 1989, he founded and
served as a Director of Innotech, Inc., an ophthalmic manufacturing system. From 1982-
1984, he was VP of Marketing and Sales of Immuno-Modulators Laboratories, Inc., an
emerging biopharmaceuticals company. From 1976-1982, he was Assistant Professor of
Education at University of Houston.
Berneman is a Past President of AUTM and a former Vice President and Trustee of the
LES (USA & Canada). Dr. Berneman is the 2005 recipient of the LES Barnes Mentoring
Award.
Dr. Berneman is a Certified Licensing Professional (CLP) and holds a baccalaureate
degree in history from the Pennsylvania State University, a teaching credential from
University of California at Santa Barbara, and masters and doctoral degrees in education
from Teachers College, Columbia University.
[back to top]
Adrienne Blanchard
Adrienne Blanchard practices in the areas of pharmaceutical policy and regulation, as well as in the field of trade marks in the firm's Ottawa office. She is Vice-Chair (Biotech) for the firm's Life Sciences Industry Group.
Called to the Ontario Bar in 1994, Ms. Blanchard has a Bachelor of Commerce degree from Dalhousie University and received her LL.B from the University of Saskatchewan in 1992.
Ms. Blanchard joined Gowlings in 1998. Ms. Blanchard is a member of the Intellectual Property Institute of Canada (IPIC) where she has chaired the IP Trade Policy Committee since 1999. She is a member of BIOTECanada's Health Policy Advisory Board, and a member of the Intellectual Property Owners' Association's committee on Pharmaceutical Issues. She is a registered lobbyist for the pharmaceutical industry.
Ms. Blanchard is founding Executive Editor of Drug Pricing and Reimbursement @ Gowlings, an electronic newsletter published by Gowlings. Ms. Blanchard, along with partner Jane Steinberg, is co-editor of the publication Life Sciences Law in Canada, a looseleaf text released in October 2006 by Carswell (updated twice yearly). Ms. Blanchard is co-author of the text "Practical Guide to IP Issues in the Pharmaceutical Industry", published by EIPR/Sweet Maxwell, in 2007.
[back to top]
Rochelle Blaustein
Rochelle Blaustein serves as the Director of Technology Transfer and Development at the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. She oversees the intellectual property of the NIDDK, including inventions and agreements relating to collaborative research. Prior to joining the NIH, Ms. Blaustein was in private law practice, concentrating in intellectual property. She served as subject matter expert for the National Technology Transfer Center, creating and delivering courses to NASA personnel. She was an Assistant Professor of Law at the Pierce Law Center where she taught government officials and attorneys from 35 countries, as well as traditional law students. In addition to teaching intellectual property law, she designed and taught a 30-hour negotiation skills workshop. Ms. Blaustein holds a bachelors from Yale University where she studied molecular biology and received laboratory training in human gene mapping and clinical cytogenetics at the Yale School of Medicine.
[back to top]
Donald M. Boles
Mr. Boles earned his Bachelors degree in Electrical Engineering and his Juris Doctor from the University of Dayton in 1976 and 1979 respectively. He started his career in law at Westinghouse, moving to AMP in 1982 where he handled all of the company 's Pacific Rim IPR activities. In 1992, he began work for Siemens Corporation handling several large business units. In 1997, Don became the Vice President of Intellectual Property for InterDigital Communications Corporation. InterDigital is a recognized pioneer in the architecture, design, and delivery of advanced wireless technology platforms. He has since been promoted to Senior Vice President level holding the title of Chief Patent Strategist and also holds the position of Vice President of Intellectual Property and Chief Patent Counsel of InterDigital Technology Corporation, a subsidiary that holds issued and pending patents and is a member of the board of Directors for IPR Licensing and Tantivy Communications. As a member of LES he is also a Certified Licensing Professional.
During his tenure at InterDigital, the company has grown the patent portfolio over tenfold with 163 US Patents issuing in 2007 making it approximately 122 in the world for the most issued patents in 2007. He is integral in developing and executing licensing strategies of the patent portfolio. He is very active in Asia, traveling there monthly engaging industry and government groups for the purpose of licensing the companies patent portfolio.
[back to top]
Russell Boltwood
Russell Boltwood joined UTStarcom in December 1997 as its first Director of Law and Human Resources. He oversaw the Company 's legal and human resources functions through its successful IPO in 2000, as well as through its expansion into India, Japan, Europe and South America. In 2007, Russell became the Company 's first Vice President of Licensing and Intellectual Property, and presently oversees the Company 's patent and intellectual property licensing matters. Russell holds a B.A. in Economics from the University of California, Berkeley, a J.D. from Golden Gate University in San Francisco, and is a graduate of the Executive Program at Stanford University 's Graduate School of Business in Palo Alto, California. Russell is a member of the State Bar of California, and has authored a number of articles regarding intellectual property, including "Basic Patent Law in Brazil, And Recent Developments," an article published in the January 2008 edition of the International In-House Counsel Journal (www.iicj.net). Russell also provides regular comment on IP development and management issues via his blog at www.ip-transactions.typepad.com.
[back to top]
Ben Bonifant
Ben Bonifant is an experienced consultant to leaders of global pharmaceuticals and biotechnology organizations and to decision makers of large private equity funds. Mr. Bonifant has been a management consultant for more than fourteen years. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals. Recent by-lined articles have appeared in Pharmaceutical Executive, Chemical Specialties, and Business Horizons. He is the author of the chapter, "Market Segmentation and New Product Development" in the recent update to The PDMA Handbook of New Product Development. In addition, Mr. Bonifant has written case studies on the pharmaceutical industry used in graduate business programs. He has been a guest lecturer at the Fuqua School of Business, the Indiana University Kelly School of Business, and many industry conferences in the US and Europe. Mr. Bonifant earned an M.B.A. from the Stanford Graduate School of Business and a B.S. in mechanical engineering from Duke University.
[back to top]
Barry Brager
Barry Brager is the Founder and Managing Partner of Perception Partners®. He is responsible for diverse teams, tools and techniques that help clients understand, quantify and maximize the value from innovation and intellectual property. In this role, Barry leads the deployment of technology investment, business development and intellectual property transaction Solution Suites that have supported decisions related to more than $1 billion in financial transactions.
Barry holds several leadership positions in the IP industry. He is the Small Business Committee Chair of the Intellectual Property Owners Association. He is also the co-chair of the Atlanta chapter of the Licensing Executives Society and will co-chair the LES 2008 Annual Meeting in Orlando. At the meetings of these groups and others, Barry is a frequent speaker on IP strategy, valuation and the links between analyzing innovation and discovering competitive advantage.
Barry graduated in 1992 from Temple University, and in 2003 completed Emory University's top 10 globally-ranked Executive MBA program, graduating Beta Gamma Sigma and first in his class.
[back to top]
Gregory B. Brown, M.D.
Dr. Brown is a founder, Managing Director and a member of the CHRP Investment Committee. Previously, Dr. Brown was a partner at Paul Capital Partners where he was responsible for global sourcing for the Paul Royalty Funds in addition to being primarily responsible for the execution and management of more than $235 million in royalty-related investments. While at Paul Capital from 2003-2006, he co-managed the Paul Royalty Funds and served on that firm's operating committee. Prior to that, Dr. Brown was the co-head of investment banking at Adams, Harkness & Hill (now Canaccord Adams) where he worked from 1997-2002. From 1992-1997, Dr. Brown was at Vector Securities both as a healthcare investment banker and a Wall Street Journal "All-Star" biotechnology research analyst. Dr. Brown has been a practicing thoracic and vascular surgeon and founded an HMO prior to attending business school as a Merck fellow. He currently serves on the boards of Oscient Pharmaceuticals and MonoSol Rx, and had been an observer on the board of Acorda Therapeutics. Dr. Brown holds an A.B. from Yale College, an M.D. from S.U.N.Y. Upstate Medical Center, and an M.B.A. from Harvard Business School.
[back to top]
John Browning
Mr. Browning, a Vice President at Analysis Group, Inc., is an economist who specializes in intellectual property valuation and damages analysis. His litigation and arbitration experience has included assisting experts in developing expert testimony for patent infringement, breach of contract and antitrust matters as well as evaluating opposing experts' damages analyses. His case work has spanned a variety of industries including health care, computer software, consumer durables, automotive, telecommunications and media. Mr. Browning previously taught microeconomics at the University of Chicago.
[back to top]
Michael W. Broxson
Mike Broxson is Director of Global Licensing at Takeda Pharmaceuticals North America, the U.S. affiliate of Takeda Pharmaceutical Company of Osaka, Japan. He is responsible for global licensing activities in cardiovascular, endocrinology and genito-urinary therapeutic areas, and also has corporate development responsibilities. Mike has been the transaction lead for several Takeda collaborations, most recently for the global partnership with Cell Genesys Inc. for prostate cancer immunotherapies. During his tenure in business development, he has played a key role on many Takeda alliances, including those with Eli Lilly, Kos, Cephalon, Merck KGaA, Affymax, H. Lundbeck, and Millennium. He also spent several years in new product planning and finance roles at Takeda.
Prior to Takeda, Mike worked as a consultant at CH2M Hill, a global environmental engineering firm, and began his career in academics at Tulane University’s Center for Bioenvironmental Research, studying the effects of environmental estrogens on aquatic ecosystems. Mike earned B.S. (economics) and M.S.P.H. (toxicology) degrees from Tulane University, an M.B.A. (finance and econometrics) from the University of Chicago Graduate School of Business, and is a CFA (Chartered Financial Analyst) charter holder.
[back to top]
Timothy R.M. Bryant
Timothy R.M. Bryant is a partner in the law firm of McDermott Will & Emery LLP based in the Firm's Chicago office.
Tim has a national corporate transactional practice. He focuses on mergers and acquisitions, leveraged buyouts and venture capital and royalty financings.
For several years, Tim led the Firm's corporate practice in Silicon Valley, where he counseled venture capital funds and information technology and biotechnology companies in a wide variety of transactions.
Tim is recognized as one of the leading corporate health care lawyers in the United States by many legal directories. Chambers & Partners USA ranks Tim as a leading private equity lawyer. Who's Who Legal rates Tim as one of the top 20 M&A lawyers in Chicago.
[back to top]
Jim Burger
Jim Burger is a member of Dow Lohnes specializing in the representation of technology companies on intellectual property, communications, and government policy matters. Jim joined the firm 's Media, Information and Technologies group in January, 1997. Before Dow Lohnes, Jim was a Senior Director in Apple Computer 's Law Department. Jim has worked extensively on legal and policy issues arising from the confluence of digital technology, communications, IP protection and government regulation, particularly as affecting digital content, DTV, wireless data, and the Internet. He currently serves as the Co-Chair of FCBA 's Intellectual Property Committee. Jim was named in the 2007 and 2008 Washington Post, The Best Lawyers in America in the specialty of Technology Law. Jim received his Bachelors (with Honors) and Masters from New York University and his Law (cum laude) degrees from New York University School of Law, where he served as an editor of the NYU Law Journal.
[back to top]
Bradley L Campbell
Mr. Campbell joined Amicus in May 2006 as Senior Director of Business Development and became Vice President of Business Planning in April 2007. Prior to Amicus, Mr. Campbell served as Business Director of Genzyme Cardiovascular, responsible for business development, commercial planning and alliance management for cardiac gene therapy programs. Previously, he was the Sr. Product Manager for Myozyme®, Genzyme's enzyme replacement therapy for Pompe disease. He has also served in sales & marketing for Bristol-Myers Squibb, and as a business strategy consultant for Marakon Associates. Mr. Campbell has been active in a number of philanthropic organizations, and is currently the President of the Board of Directors of the National Tay-Sachs and Allied Diseases Association.
Mr. Campbell received his B.A. in Public Policy Studies from Duke University and his M.B.A. from Harvard Business School.
[back to top]
John Cantello
John Cantello is currently Director, Transactions in GlaxoSmithKline's (GSK) Worldwide Business Development Group and is also a member of Leadership Team for GSK's Center of Excellence for External Drug Discovery (CEEDD). In this role, John is primarily responsible for setting the business development strategy for the CEEDD and managing the sourcing and transactions of all CEEDD strategic discovery & development alliances. Over the past three years, John has contributed to the establishment of the CEEDD alliance portfolio (7 new alliances beginning in 2006) and has led the Targacept, Inc. and Praecis Pharmaceuticals transactions; the latter of which resulted in an acquisition by GSK in 2007. Prior to his current role, John spent three years in the GSK Worldwide Business Development group scouting and securing access to platform technologies that could enable the early stages of GSK drug discovery and development across all major therapeutic areas. Prior to joining GSK, John was employed by other large pharma (Bristol-Myers Squibb), mid-size biopharmaceutical (Regeneron Pharmaceuticals) and venture-backed start-up biotechnology companies (Morphochem AG; formerly Small Molecule Therapeutics, Inc.) where he held various roles of increasing responsibility that spanned drug discovery, project management and business development. John received his PhD in molecular Virology from the University of Delaware and post-doctoral training in gene therapy at the California Pacific Medical Center, San Francisco, CA.
[back to top]
Susan A. Capello
Susan A. Capello is a Senior Intellectual Property Attorney for Intel Corporation. She graduated from West Chester University of Pennsylvania with a Bachelor of Science in Chemistry/Biology and Business Administration and worked in scientific research capacities with Hoffman-LaRoche, Inc. and the Rorer Group, Inc. Ms. Capello received her Juris Doctor from Pace University School of Law in 1989 and spent several years in private practice before becoming an in-house IP attorney. As in-house counsel she has worked for Becton, Dickinson and Company; Lipid Sciences, Inc. and Connetics Corporation.
[back to top]
Mary Ann Capria, Esquire
Mary Ann Capria, Corporate Counsel for DuPont Legal, has over 24 years experience in all aspects of Intellectual Property and Commercial law. She has represented a wide variety of companies to achieve a wide variety of business goals - from start-ups, recent IPO, to companies in the Fortune 100, involving many technologies (IT, software, life sciences, chemical arts, electrical arts, and mechanical arts).
Her experience includes:
- Clerk, U. S. Court of Appeals for the Federal Circuit
- Fellow, Kyoto Comparative Law Center, Kyoto, Japan
- Private Practice: All aspects of patent preparation and prosecution, licensing, development agreements, alliances, opinions, counseling, due diligence, and complex litigation (Federal courts, ITC, arbitration, and mediation with respect to patents, trademarks, trade secrets, and licenses), mergers and acquisitions, and other commercial transactions.
- Finnegan, Henderson, Farabow, Garrett & Dunner (DC office)
- Jones Day Reavis and Pogue ( DC office)
- Birch Steward Kolash & Birch (VA office)
- Alston & Bird (DC office) - Technology Practice Group and DC Office 's, Chair of Life Science Group
[back to top]
David Cassak
One of the leading experts on the medical device industry, David Cassak writes and speaks extensively on trends and company strategies focusing on all aspects of the medical device industry. He is a frequent presenter before companies and industry groups, including, for the past several years, the featured interviewer at the Stanford University BioDesign Program's Innovator's Workbench series.
David was for almost 20 years Managing Partner, running the medical device business, of Windhover Information Inc., which he founded in 1989 with his partner Roger Longman. In 2004, Windhover acquired MedTech Insight, an information provider specializing in the medical device industry, and in 2008, Windhover was acquired by Elsevier Life Sciences Inc. Under Elsevier, David will run a newly-created business unit that features several leading publications serving medical device executives, including IN VIVO, Start-Up, MedTech Insight, and the Gray and Silver Sheets. In addition, the new unit will oversee the IN3 investor/partnering meetings, the MedTech market research reports business, and the device modules in Windhover's M&A, alliance, and financing transactions database
[back to top]
David Cavallaro
David J. Cavallaro, CLP, AVA, is a Manager in Stout Risius Ross ' Dispute Advisory & Forensic Services Group. He has extensive experience providing a broad range of business and financial advice to trial lawyers and in-house counsel throughout the dispute process, including matters involving intellectual property infringement, anti-trust and securities litigation, breach of contract, post-merger and acquisition disputes, bankruptcy, divorce and shareholder disputes. Mr. Cavallaro 's experience encompasses a wide array of industries, including health care, medical devices, manufacturing companies, automotive suppliers and OEMs, telecommunications, transportation, marine, food and beverage, media, environmental services, publishing, mortgage and banking and aggregates. Mr. Cavallaro has lectured at universities, presented continuing education seminars and published articles on the subjects of litigation advisory services and economic damages. He is a member of the Licensing Executive Society, the National Association of Certified Valuation Analysts and the Intellectual Property Owner 's Association, where he serves on the Damages and Injunctions committee.
[back to top]
Linda Chao
Linda Chao is a Senior Licensing Associate in Stanford University's Office of Technology Licensing (OTL). At OTL, Linda manages an intellectual property portfolio of over 280 inventions, including nanotechnology, photonic, semiconductor, and bioengineering technologies, and negotiates licenses with companies ranging from start-up ventures to Fortune 500 companies. She is the OTL representative to the Stanford Entrepreneurship Network, which is a federation of entrepreneurship-related organizations across the Stanford campus. Linda is also an active member of the Licensing Executives Society (LES), including board member of the LES Foundation (a Foundation of LES U.S.A. & Canada), and chair of the 2009 LES Foundation Graduate Student Business Plan Competition. Her technical and business experience includes microprocessor design at Digital Equipment Corporation, industry analysis at SEMATECH, and product marketing at Applied Materials. She is a registered USPTO patent agent and a Certified Licensing Professional. Linda received a Bachelor of Science in Electrical Engineering, a Master of Science in Electrical Engineering, and a Master of Science in Management from Massachusetts Institute of Technology.
[back to top]
Mitchell Charness
Mitchell Charness is a partner of Ridout & Maybee LLP in the firm 's Ottawa
office. His practice covers mechanical patents, trade-marks, licensing and litigation. He
has appeared numerous times before the Federal Court, the Federal Court of Appeal
and the Trade-marks Opposition Board. Mitch was called to the Bar in Ontario
in 1995 and prior to joining private practice, he clerked with the Federal Court
of Canada.
Mitch has a B.A.Sc. in Mechanical Engineering from the University of Waterloo
and an LL.B. from the University of Ottawa.
He is also a part-time Professor at the University of Ottawa Law School,
teaching a course in Advanced Trade-marks law and is a frequent speaker on
intellectual property topics for various organizations, including the University
of Ottawa School of Engineering, Carleton University, Algonquin College,
the National Judicial Institute and the Canadian Intellectual Property Office.
[back to top]
Alex Chausovsky, PhD
Primarily responsible for design and execution of discontinued drug in-licensing and development program.
Has comprehensive industrial expertise and knowledge in molecular cell biology and R&D process management. Prior to joining Optimata, Dr. Chausovsky has been involved in R&D management as VP R&D and VP Product Development of Zetiq Technologies Ltd., QuantomiX and NVR labs. Holds a PhD in Molecular Cell Biology from the Weizmann Institute of Science, Israel and Postdoctoral training at Northwestern University, USA.
[back to top]
Constantine Chinoporos
Mr. Chinoporos currently leads the Transactions and Partnering function within the Corporate Development group at Genzyme. His team provides transactional support to Corporate and Business Unit partnering and acquisition initiatives, valuation analysis, and support in structuring and executing negotiations with potential partners. He has been with Genzyme for approximately seven years.
Prior to joining Genzyme, Mr. Chinoporos worked at Eli Lilly and Company for twelve years. He held positions with market research, sales management, and finance. He spent his final five years as part of the Corporate Finance & Investment Banking team and then the Alliance Management function.
Mr. Chinoporos holds two degrees from Cornell University: a BA in History as well as an MBA.
[back to top]
Ashok Choudhury
Ashok Choudhury is a Senior Commercialization Associate at Vanderbilt University’s Office of Technology Transfer and Enterprise Development. Ashok has sixteen years of experience in both national laboratory and university technology transfer, primarily in the physical sciences. In addition to his technology transfer responsibilities, Ashok teaches Materials Science at Vanderbilt’s School of engineering. Ashok has received teaching awards from universities and professional organizations and has also co-authored two books in failure analysis. Ashok is a member of AUTM and LES.
[back to top]
Stephen Y. Chow
Stephen Y. Chow is a partner at the Boston law firm, Burns & Levinson, and practices in the development, assertion, licensing and litigation of patent, copyright and trademark portfolios for enterprises and institutions leading in technologies including biomedical, computer, e-commerce, financial and telecommunications, as well as in their financing. He earned two Harvard degrees, an A.B. in Physics and Philosophy cum laude and an S.M. in Applied Physics, worked on the Princeton controlled nuclear fusion project, and received his law degree from Columbia.
Steve works on legislation in the intersection of international commercial and intellectual property law as a member of the National Conference of Commissioners on Uniform State Laws. He is the author of the legal treatise, E-Commerce and Communications, published by Matthew Bender/Lexis-Nexis. Steve has taught "Counseling Technology-Leading Emerging Enterprises" at Suffolk Law School since 1995 and has a particular interest in the trading of intellectual property rights.
[back to top]
David Christie, BSc (Biology), MBA
David Christie has over 25 years of sales, marketing, operations, and senior management experience in the medical device and high technology industries. David joined Pyng Medical Corp. in November 2006 to execute an enhanced Strategic Business Plan designed to ramp-up revenues and broaden the product portfolio.
Pyng commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng's product portfolio includes a variety of innovative, lifesaving tools.
Fiscal 2007 results demonstrated 60 % revenue growth compared to 2006 and more than a ten-fold increase in income. Pyng is on-track to double its revenue in David's first two years.
The Company recently acquired three trauma products from BCI International, and received the 2008 Medical Device Company of the Year Award from LifeSciences BC.
During a previous role as Chief Operations Officer at VSM MedTech Ltd, the Company progressed from zero revenue to $15 million in three years and grew from 12 employees to 175 employees.
[back to top]
Mary Beth Cicero, CLP
Mary Beth Cicero is President of MarketSense Ltd., a consulting firm specializing in Healthcare Marketing & Business Development. MarketSense was founded in 1995 with a focus on the intersection of business development and marketing, including licensing and co-promotion arrangements, as well as marketing analyses, forecasting, opportunity assessments and due diligence. Ms. Cicero has over twenty years of experience working with pharmaceutical and biotechnology companies and has worked with over fifty clients. Her previous positions include Vice President of Business Development at two biotechnology companies and Executive Director of Marketing at Serono where she was responsible for all U.S. marketing activities, as well as new product planning and licensing. She also spent seven years at Rhone Poulenc Rorer where she headed up marketing at Dermik Laboratories, now a subsidiary of sanofi-aventis.
In addition to her professional responsibilities, Ms. Cicero is a part-time Professor at Northeastern University's Graduate School of Business and has taught a course on Healthcare Marketing. She is a former member of the Board of Trustees of the Licensing Executives Society (LES) and Chair of the LES Health Care Committee. Ms. Cicero also teaches the LES Professional Development course. She was on the Board of Directors of the National Psoriasis Foundation and has served as Treasurer. Her educational background includes a BS in Biology cum laude from Boston College and an MBA from Babson College. She recently earned the Certified Licensing Professional™ (CLP) credential.
[back to top]
Hugh M. Cole
Hugh Cole joined Shire in April 2007 as Vice President of Business Development for Shire HGT. While at Shire, Hugh has led three major in-licensing/acquisition transactions - with Amicus Therapeutics, Zymenex, and Jerini AG. Prior to joining Shire, Hugh was Vice President of Corporate Development at Oscient Pharmaceuticals and, prior to that, held business development and new business planning roles at Millennium Pharmaceuticals. Hugh has completed numerous transactions in his business development career, including in-licensing, out-licensing, co-promotion, and merger/acquisition transactions. Before joining the biopharmaceutical industry, Hugh spent several years in the investment management and management consulting fields.
Education
AB (Chemistry), Harvard University
MBA (Finance and Health Care Management), The Wharton School, University of Pennsylvania
[back to top]
Hugh Cole
Hugh Cole joined Shire in April 2007 as Vice President of Business Development for Shire HGT. Prior to joining Shire, Hugh was Vice President of Corporate Development at Oscient Pharmaceuticals and, prior to that, held various business development and new business planning roles at Millennium Pharmaceuticals. Hugh has completed numerous transactions in his business development career, including in-licensing, out-licensing, co-promotion, and merger/acquisition transactions. Before joining the biopharmaceutical industry, Hugh spent several years in the investment management and management consulting fields. Hugh has BA in chemistry from Harvard and an MBA from Wharton.
[back to top]
Dr. Teresa Colella
Dr. Teresa Colella is a Technology Manger at the Applied Physics Laboratory.
Previously, she worked for over four years as a Registered Patent Agent at
Sterne, Kessler, Goldstein and Fox. Dr. Colella carried out post-doctoral
research at Johns Hopkins School of Public Health, obtained her Ph.D. in Microbiology/Immunology
at the University of Virginia, and her B.A. from Wellesley College. She
is an MBA candidate at Loyola College.
[back to top]
Warren Cooper
Warren Cooper is CEO of Prism Pharmaceuticals, a venture-backed specialty company focused in acute cardiovascular therapeutics. Prism submitted its first NDA in early 2008, just two years after in-licensing this compound, and plans to launch its first product in 2009. Prism is structured around a blend of conventional and alternative financing. Warren is a UK-trained physician with over 28 years experience in the pharmaceutical industry, including 12 years with Merck, in roles ranging from a clinical research physician to head of Worldwide Clinical Research Operations across all therapeutic areas. He moved to the Philadelphia area in 1992 with the formation of AstraMerck (now AstraZeneca PLC), and led that company's cardiovascular business division. Warren then founded a healthcare consulting practice, Coalescence Inc., which he led for five years prior to starting Prism.
[back to top]
Walter G. Copan
Dr. Walter G. Copan is Executive Vice President - North American Operations and Chief Technology Officer for Clean Diesel Technologies, Inc., Stamford, Connecticut, U.S.A. The focus of this role is bringing clean energy, energy efficiency and environmental technologies to global transportation and distributed power markets. He was previously Principal Licensing Executive at the National Renewable Energy Laboratory (NREL) of the U.S. Department of Energy. There his responsibilities included the licensing and commercialization of energy related technologies, new enterprise development, and partnerships with industry, academia and government.
Prior to joining NREL, Dr. Copan was Managing Director, Technology Transfer and Licensing for The Lubrizol Corporation, responsible for corporate venturing and new business development. Previous assignments in Dr. Copan 's 28 year career with Lubrizol include leadership roles in research, product development, strategy, new ventures, business development and commercial management. He also headed Lubrizol Petroleum Chemicals Technology based in the U.K., with responsibility for product development, program management and technical service for Lubrizol 's business in Europe, the Middle East, Africa and the Former Soviet Union.
He received his Ph.D. in Physical Chemistry from Case Western Reserve University, and his undergraduate degrees from CWRU are in chemistry and music. He has authored numerous professional publications and presentations, and serves on the boards of directors for several organizations. Dr. Copan has been an active member, committee chair, trustee, and officer of the Licensing Executives Society (LES) USA & Canada and LES International. He currently is LES Vice-President, U.S.A. Region, and within LESI is Chair of the Industry-University and Government Transactions committee. He also served as member of the National Advisory Council to the U.S. Federal Laboratory Consortium. Other professional associations include the Society of Automotive Engineers and the American Chemical Society.
[back to top]
Doug G. Copland
Doug G. Copland is a partner in the Vancouver office of Borden Ladner Gervais LLP, a Canadian national law firm with over 700 professionals across Canada. Doug practices in the areas of corporate/commercial, technology and intellectual property law. Doug is a member of the International Trademark Association, the Intellectual Property Institute of Canada, and the Licensing Executives Society, and will serve as the incoming Chair of the LES High Tech Sector Software Committee for 2008 - 2009 and Chair of that committee for 2009 - 2010. Doug has previously written and spoken on a variety of topics in the areas of technology and intellectual property law, including trademarks and domain names on the internet, due diligence and representations and warranties in intellectual property transactions, Year 2000 issues, international licensing and joint venture transactions, and electronic commerce, and he is the co-editor of the Canadian publication "Consolidated Electronic Statutes and Regulations with Related Materials". Doug is listed in the Intellectual Property category of the 2008 edition of "Best Lawyers in Canada".
[back to top]
Carlos A. Coroalles, CLP™
Carlos is currently Vice President of Licensing at Jarden Consumer Solutions [JCS], a division of Jarden Corporation [NYSE-JAH] based in Boca Raton, Florida. He joined the company in March 2005 to develop brand extension strategies for JCS' growing, world wide portfolio of consumer product brands including, Bionaire, Crock-Pot, Health-o-Meter, Food Saver, Mr. Coffee, Sunbeam and Oster. He is responsible for the execution of both in-bound and outbound licensing initiatives. After graduating from Fordham University, he began his career at JC Penney's Corporate Offices in New York City holding various positions in the Retail Buying Division. In 1988 he began his licensing career at Springs Industries, then a holder of various trademark licenses for the home furnishings industry. In 1991 he was named Manager of Licensed Products for Fisher-Price, a leading manufacturer of pre-school toys and a division of Mattel, Inc. In 1997 he became Director of Licensing for Disney Consumer Products, Latin America responsible for key product categories throughout the region in Argentina, Chile, Colombia, Brazil, Mexico and Venezuela. In 2000 he joined Motorola as Director of Product Development for the Cellular Division managing a portfolio of cell phone accessory items working with teams throughout the world. In 2003 he was named Director of Trademark Licensing, Worldwide.
Carlos is a member of L.E.S. and LIMA and has spoken at key industry events on issues regarding the business of trademark licensing.
[back to top]
John Cosmopoulos
John Cosmopoulos has worked at Tufts University since September 2001 as Senior
Manager, Business Development in the Office for Technology Licensing & Industry
Collaboration where he is the primary case manager for the Schools of Medicine
and Dental Medicine and also manages projects for the Schools of Veterinary
Medicine and Nutrition. In this capacity, he manages all aspects of the technology
transfer process from faculty outreach, evaluation of new invention disclosures,
marketing, negotiations, agreement drafting and he has successfully concluded
a wide range of option and license agreements, sponsored research agreements,
IP agreements, collaboration agreements, as well as facilitated the formation
of start-up companies. Prior to Tufts University Mr. Cosmopoulos started his
career in technology transfer at the University of Ottawa where in 1996 he
was hired as its first full-time technology transfer professional. Mr.
Cosmopoulos has an undergraduate education in biology from the Aristotle University
of Thessaloniki, Greece and a M.Sc. degree in molecular biology from Carleton
University and a MBA degree from Queen 's University.
[back to top]
John Cronin
John Cronin is Managing Director and Chairman of ipCG. Capitalizing on a lifelong study of creative and inventive thinking processes, business strategy development, and transaction negotiations, John has created the unique ipCapital System® methodology, which extracts and documents invention, identifies opportunity and risk, drives transactions to completion, and creates significant market value from IP. Over the years, he has become a respected thought leader among executives who wish to align business issues and IP and translate strategies into actionable financial results. John holds a BSEE, an MSEE, and a BA degree in Psychology from the University of Vermont.
[back to top]
Luciano Daffarra
Luciano Daffarra is the founding partner of Daffarra & Partners. Before
going into private practice, he was part of the legal offices of big Italian
corporations operating, among others, in the broadcasting field.
As a lawyer, he subsequently represented and currently represents many
producers, distributors and artists active in all media sectors. He is a member
of the Permanent Consultative Committee for Copyright at the Italian
Prime Minister 's Office and is Secretary General of the Italian Federation
Against Audio-Visual Piracy (www.fapav.it).
Mr. Daffarra is a also member of the American Chamber of Commerce in Italy
(www.amcham.it ),
as President of the Intellectual Property Committee since 1996, and on the
Board of Directors of the Chamber since 2003. In the above capacities, he
collaborates with the Italian Government offices in charge of enforcing and
drafting amendments to the Italian Copyright Law, and has dealt with major
problems relating to copyright and intellectual property in Italy, the European
Union and the United States.
Mr. Daffarra is a frequent speaker and lecturer at courses, seminars and
conferences dealing with intellectual property law. He is a founding
member of the Italian organizations AGICA (Association of Cinema and Audio-Visual
Lawyers) and IPLAW (Association for Intellectual Property Rights and Competition www.iplaw.it)
[back to top]
Debi Davis
Debi is an associate in the Technology Transfer Office at the MITRE Corporation, a not-for-profit organization managing federally funded R&D centers. MITRE generates intellectual property from its government funded work program and its independent research and development program. She is involved with the management of the company's diverse intellectual property portfolio and licensing activities. Since joining MITRE in 1999, she has held analyst and communications positions in MITRE's finance group, and joined MITRE's TTO in 2005.
Her past professional responsibilities have included new business development in the environmental industry, analysis of emerging markets in Central Europe, marketing and communications. She holds a B.A. in Political Science from Southern Methodist University in Dallas, Texas, and is an MBA candidate at the University of Maryland.
[back to top]
Pamela Demain
Pamela Demain is Executive Director, Corporate Licensing at
Merck & Co., Inc. She has been at Merck for twenty-five years.
For twelve years, she has been responsible for negotiating transactions
with companies, universities and institutions worldwide, including
arrangements for compounds, research collaborations, patents, formulations
and research platform technologies. Pam also heads up the relationship
development area, which involves initiating new business development
opportunities. Prior to her current position, Ms. Demain was
in charge of the Business Information & Research Group in the Worldwide
Human Health Marketing area of Merck, providing strategic decision
support for new and in-line products.
Previous positions at Merck include Corporate Planning, Marketing Communications
and Product Management, where she was responsible for the worldwide launch
of PRIMAXIN/TIENAM. She joined Merck in 1981 as part of a management
training program.
Pamela 's pharmaceutical career began in the natural products laboratory
of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary
of the Dow Chemical Company. Ms. Demain is a graduate of the University
of Massachusetts at Amherst, and holds a M.B.A. in International Business
from The American University in Washington, D.C.
[back to top]
Brad DeSandro
Brad DeSandro is with the Intellectual Property (IP) practice group of Quarles & Brady LLP. As an IP strategist, a significant portion of his practice is devoted to matters involving intellectual property procurement and licensing, preparing intellectual property opinions, and drafting intellectual property license agreements. Mr. DeSandro's practice also includes patent disputes, including pre-litigation investigations, analyses and negotiations. He has drafted and prosecuted hundreds of U.S. and foreign patent applications in a variety of technologies. Mr. DeSandro, a former U.S. Patent Examiner, has over twenty years of technical experience with software, semiconductor and mechanical technologies, including many years of direct software development work experience.
Mr. DeSandro's recent experience includes:
- Medical device, software, semiconductor, and business method patent applications, infringement and validity opinions.
- Counseled startup companies on developing intellectual property strategies.
- Negotiated and drafted numerous technology licensing agreements.
- Represented a major software company, a major semiconductor company, and multiple healthcare organizations in patent licensing and procurements.
Mr. DeSandro is a Certified Licensing Professional (Certificate No. 1230) and member of the Licensing Executive Society (LES), where he is a faculty lecturer in the LES Professional Development Series. He is also a member of the American Intellectual Property Law Association (AIPLA) in which he has held various leadership positions.
[back to top]
Frank DiCosmo
Frank DiCosmo is the President and Chief Executive Officer of Covalon Technologies Ltd., a company that actively researches, develops, manufactures and licenses collagen-based soft tissue repair matrices, related medical devices and anti-infective, silver ion-releasing and drug-releasing coatings and biomaterials for medical devices for the USA, Canadian and international markets. Covalon also has strong R&D program in regenerative medicine targeted to de novo angiogenesis targeted to regenerative medicine.
Frank has a Ph.D. (1981) in Biology from the University of Waterloo, Canada. Prior to co-founding Covalon in 1999, Frank was a professor at the University of Toronto for 22 years. Frank is a founding partner of Covalon Technologies Ltd. and co-inventor of Covalon’s intellectual property. He is a member of the Institute of Corporate Directors (Canada) and has served Covalon as Chief Scientific Officer, Chairman of the Board, and currently is the President and Chief Executive Officer.
[back to top]
Richard Ding
Richard Ding is VP for Strategy, Business Development & Theranostics, bioMerieux and CEO of bioTheranostics, a company of bioMerieux.
Richard has over 15 years of management experience in the pharmaceutical and biotech industry and has held various positions in strategy, licensing, research and manufacturing in Eli Lilly and company and Myriad Genetics. Richard holds an MBA and Master degree in biology.
[back to top]
Eric L. Dobmeier
Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications, strategic marketing and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the worldwide license agreement with Genentech on SGN-40, the in-license of SGN-33 from PDL BioPharma and ADC collaborations with CuraGen, Progenics, Bayer, MedImmune and Agensys. He has also participated in raising over $200 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from Boalt Hall School of Law, University of California, Berkeley and an undergraduate degree from Princeton University.
[back to top]
Don Drinkwater
Mr. Drinkwater currently directs the licensing group for a major consumer electronics company.
Mr. Drinkwater has contributed to the Consumer, Computer and Networking industry for over twenty years. He has held principal engineering and senior management level positions including group manager of Digital Equipment Corporation 's and Compaq Computer Corporation 's Corporate Licensing Office. Don worked with clients to improve intellectual asset utilization while at Standard and Poors and PricewaterhouseCoopers and served as director of licensing for 3Com Corporation.
Mr. Drinkwater has a Bachelor of Science Degree in Electrical Engineering from the University of Massachusetts at Lowell, a Master of Science Degree in Electrical Engineering from Worcester Polytechnic Institute, and a Master of Business Administration from Clark University. Don is a member of Eta Kappa Nu (the honor society of the Institute of Electronic and Electrical Engineers ("IEEE") and won the Haskell Memorial Award for distinguished teaching at the University of Massachusetts at Lowell. Mr. Drinkwater holds seven patents.
Mr. Drinkwater has published articles in les Nouvelles (the Journal of the Licensing Executive Society, "LES") and IEEE publications. He is a member of the IEEE, LES, and spent fifteen years serving as an adjunct faculty member at the University of Massachusetts at Lowell.
[back to top]
Ben du Pont
Ben is co-founder and President of yet2.com, a global marketplace for technology. Founded in 1999, Yet2.com creates mutually beneficial partnerships between companies leveraging new technology and patents. yet2.com was one the worlds first Open innovation platforms. 1/4 of the Fortune 500 directly engage yet2.com and most of the Fortune 500 are engaged in deal disucssions through yet2.com, in deals ranging from new drug delivery technologys to new heavy oil recovery technologies..
yet2.com has offices in; Boston, Liverpool, Tokyo and Wilmington Delaware. It was jointly funded by; Siemens, Bayer, Caterpillar, Honeywell, P&G, DuPont and NTT Leasing.
Prior to founding yet2.com, he spent 14 years with DuPont in a variety of leadership positions in; Specialty Chemicals, Fibers and Automotive business units. Ben has a 1986 BSME from Tufts University and is a director of; Morgan Stanley Capital Index NYSE:MXB, Vianix (a speech compression company), Platinum Research, Longwood Gardens, Jefferson Awards (the highest award for public service in the US) and the Tower Hill School. Ben is a licensed pilot, a ham radio operator and an avid sailor. Ben lives with his wife, Laura and 2 children in Wilmington Delaware.
[back to top]
Michael P. Dunnam
Michael P. Dunnam is a partner in the Philadelphia office of the firm Woodcock Washburn LLP. Michael received a Bachelor of Science degree in electrical engineering from Brown University in 1984 and a law degree from the National Law Center at George Washington University in 1989. Prior to joining Woodcock Washburn in 1989, Michael was a patent agent from 1986 to 1989 and a patent examiner at the U.S. Patent and Trademark Office from 1984 to 1986, where he examined color television and high-definition television applications. Michael specializes in patent procurement and strategic intellectual property counseling for creating value for new and established technology companies from procured patents through litigation and licensing. Michael is currently chair of the firm's Licensing and Business Transactions Group and is in charge of the firm's patent prosecution training program for new attorneys. Michael has written and lectured on numerous intellectual property topics, including internet business methods and the patentability of computer software and business methods.
[back to top]
David J. Dykeman
David J. Dykeman is a registered patent attorney and shareholder in the Boston office of international law firm Greenberg Traurig LLP. With over twelve years of experience in patents, intellectual property, and licensing, his practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with an emphasis on medical devices, nanotechnology, information technology, and life sciences. David has particular expertise in licensing of intellectual property and assists clients with strategies for leveraging their intellectual property portfolio for high-value commercial opportunities.
David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.
David had been selected as a Massachusetts Super Lawyer Rising Star by Boston Magazine for four consecutive years. He is a frequent conference speaker and published author on intellectual property law. David is a Contributing Editor to The Journal of BioLaw & Business, and his articles have appeared in Intellectual Property Today magazine, Boston Business Journal, Mass High Tech journal, Massachusetts Medical Law Report, Massachusetts Lawyers Weekly and Wiley Intellectual Property Law Update. David received his law degree from the University of Wisconsin Law School, and his Bachelor of Science degree in mechanical engineering from Cornell University.
[back to top]
Jacob (Jesse) N. Erlich
Jesse Erlich is a registered patent attorney, a Partner and member of the Intellectual Property / SciTech, Government Contracts and Science & Technology Groups of Burns & Levinson LLP, Boston, MA. He is a graduate of Worcester Polytechnic Institute, and has earned his J.D. from Georgetown University Law Center and a Certified Licensing Professional.
Mr. Erlich provides advice on patents and other forms of intellectual property, licensing and government related matters and is also involved with the preparation and prosecution of patent applications (U.S. and foreign).
He has contributed to numerous publications and has co-authored a book entitled, Technology Development and Transfer - The Transaction and Legal Environment, Quorum Books, 1997. He is a contributing author to 2000-2008 Licensing Update, Aspen Law & Business - a division of Aspen Publications, Inc. and Valuation of Intangible Assets in Global Operations, Quorum Books, 2001.
Mr. Erlich is currently on the faculty of the Advanced Licensing Institute at Franklin Pierce Law School. He has also sat on the faculty of The National Intellectual Property Law Institute, Postgraduate Program in Intellectual Property and The Intellectual Property Institute for Corporate Counsel, both in Washington, D.C.
[back to top]
Hon. Joseph J. Farnan, Jr.
Judge Farnan received his Bachelor of Arts degree in Government from King 's College, Wilkes-Barre, Pennsylvania, in June of 1967. Judge Farnan received his J.D. degree from the University of Toledo College of Law in June of 1970. While at Toledo, Judge Farnan was named an editor of the Law Review and awarded the Alumni Scholarship in recognition of academic achievement.
From September of 1970 until June of 1973, Judge Farnan was Dean of Students and Director of the Criminal Justice Program at Wilmington College. After leaving the college as an administrator and faculty member, he continued as a part-time instructor until 1981.
From December of 1972 until December of 1976, Judge Farnan was in the private practice of law in Wilmington, Delaware. During this time he also served as a part-time assistant public defender. From December of 1976 until January of 1979, he was appointed and served as County Attorney for New Castle County, Delaware. From January of 1979 until August of 1981, he was Chief Deputy Attorney General for the State of Delaware, and in August of 1981, he was appointed United States Attorney for the District of Delaware, where he served until his appointment to the District Court in July of 1985. Judge Farnan served as Chief Judge of the District Court from July 1997 until July 2000.
Judge Farnan is a member of the New Jersey Bar (1970) and the Delaware Bar (1972).
[back to top]
Michael J. Femal
Michael Femal is a member of the firm's Intellectual Property Practice Group and focuses his
practice principally in patent, trademark, copyright and trade secrets. For over thirty years, he
has counseled clients on all aspects of intellectual property rights, including domestic and
foreign patent, trademark and copyright preparation, prosecution and subsequent litigation
related thereto. Michael is also experienced in general legal matters such as customs, antiboycott,
antitrust, distributor relations, recalls, product liability, real estate, and construction law.
Michael Femal's IP experience includes assisting clients in negotiating and drafting their IP
licenses, joint venture and joint development agreements, brand label and secrecy agreements.
He also does IP Due Diligence work for private equity, hedge funds, banks and other companies
engaged in loans, merger and acquisitions. His extensive IP licensing experience includes deals done in the United States, Europe, Asia, South America and other foreign markets. Michael has
performed numerous IP Due Diligence investigations on mergers, acquisitions and divestitures in North and South America, Europe and Asia.
[back to top]
Steven M. Ferguson
Steven M. Ferguson currently serves as the Deputy Director, Licensing and Entrepreneurship. Prior to joining NIH Office of Technology Transfer in 1990, Mr. Ferguson served in marketing and management positions in biomedical firms subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital. Registered to practice before the USPTO, Mr. Ferguson also holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor's Degree in Chemistry (Case Western Reserve University).
Mr. Ferguson has been an economic reviewer for Maryland Industrial Partnerships (MIPS) as well as the Advanced Technology Program (ATP) grant programs and is an instructor for both the USDA Graduate School and the NIH FAES Graduate School where he is also the department chair for the new Certificate in Technology Transfer Program. Mr. Ferguson was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory and has published articles on licensing and technology transfer issues.
[back to top]
Jonathan Fleming
Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners,
an international venture capital firm specializing in life science
technology based investments, with offices in Boston and Connecticut. Mr.
Fleming has been in the investment business for over twenty years, starting
and financing growth companies in the United States, Europe, and Israel.
Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures
in Boston, MA. He began his investment career with TVM Techno Venture
Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture
Partners, a venture capital investment firm specializing in early stage healthcare
and biotechnology companies in Israel. Mr. Fleming holds a Master 's
degree in Public Administration from Princeton University and a Bachelor
of Arts degree from the University of California, Berkeley.
Mr. Fleming is a co-founder and member of the Board of Memory Pharmaceuticals
(NASDAQ: MEMY). He is also Chairman of the Board of BioProcessors Corporation
and is a director of several private companies including Leerink Swann,
a Boston based investment bank specializing in healthcare companies. Mr.
Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer
at the Massachusetts Institute of Technology.
[back to top]
Joseph D. Fondacaro, PhD
Dr. Fondacaro received his Ph.D. in Physiology from the University of Cincinnati College of Medicine. Following a 2-year postdoctoral fellowship at Albany Medical Center in New York, he spent 8 years as a faculty member at the Cincinnati College of Medicine and 15 years as a scientist and administrator in the pharmaceutical industry initially with what is now Glaxo SmithKline and later with Marion Merrill Dow. In 1996, Dr. Fondacaro joined Cincinnati Children 's Hospital Research Foundation to establish the office of technology transfer. He serves on the Board of Trustees for BioStart, a biomedical incubator and the Cincinnati Foundation for Biomedical Research and Education. He holds a faculty position at the University of Cincinnati College of Medicine and lectures on Ethics in Intellectual Property Management. He serves on several AUTM committees and has recently served as the AUTM Vice President for Professional Development. He is past chair for the Industry-University Transactions Sector of the Licensing Executive Society (LES) and co-founder and chairman of the Cincinnati Chapter of LES. He has published relevant articles on university licensing and technology transfer. Dr. Fondacaro is the founder and immediate past Director of the Center for Technology Commercialization and is currently the Executive Director for Strategic Research Alliances for Cincinnati Children 's Hospital Medical Center.
[back to top]
Scott Forbes
Scott is a Vice President in GE's Technology Ventures team. He is focused on developing GE's worldwide intellectual property and technology development programs in the high tech, medtech, and cleantech fields, particularly those related to telecommunications and microelectronics. Prior to joining GE, Scott served in Microsoft's Unified Communications group and legal department where he negotiated worldwide patent/technology licensing agreements and developed new products and online services.
Scott has held business development, regulatory compliance, and application development positions at Fortune 100 telecoms, consulting, and consumer electronics companies. He is an inventor on 30+ patent applications and has presented/published in the areas of telecoms, information security, and technology policy.
Scott is a member of LES, the IEEE, the American Bar Association, and has the CLP credential. Scott holds a Ph.D. in Telecommunications from Penn State, a law degree from George Washington University, and an M.B.A. from Indiana University.
[back to top]
Paul Germeraad
Paul Germeraad is President of Intellectual Assets, Inc., a professional advisory services firm specializing in integrated business, R&D, and IP processes. Intellectual Assets, Inc. is distinguished by using cutting edge IP assessment tools and proprietary software, in addition to offering invaluable insight based on the depth and breadth of executive level management experience and industry coverage the firm 's members represent.
Dr. Germeraad was previously Chief Operating Officer for Aurigin Systems, Inc., a software start-up company, where he focused on the development of the company 's intellectual asset management products for the Competitive Intelligence, Licensing and R&D communities. Prior to joining Aurigin in 1998, Paul worked for three Fortune 500 companies. He served as Vice President, Corporate Research for Avery Dennison, as the executive responsible for the Corporate Research Center. Before joining Avery Dennison, Paul was director of James River Corporation 's Flexible Packaging Technical Center and held a variety of R&D and management positions at Raychem Corporation.
Paul is past Chairman of the Industrial Research Institute, an organization of Chief Technology Officers whose organizations account for over 70% of all US R&D spending. Paul joined the Licensing Executives Society (LES) Board of Trustees in 2002, served as Vice President, Education in 2004, and is chair of the LESI Long Range Planning Committee. He is an instructor for the LES Professional Development Series.
Paul is a graduate of the University of California, San Diego, with a B.A. in Chemistry. In addition, Paul holds a Ph.D. in Chemistry from the University of California, Irvine and an LL.B degree from La Salle Extension University. He has also received the CLP designation from LES USA-Canada.
[back to top]
Andy Gibbs
Andy Gibbs is the Chairman and CEO of PatentCafe, a provider of Latent Semantic Analysis based solutions used for patent search, strategic portfolio management and qualitative patent analysis.
An IP Thought Leader, he was a member of the esteemed panel of participants in Building a New IP Marketplace - the IBM / NY Law School WIKI on policy and process for improving patent quality, transparency, fair valuation, flexibility and global consistency.
He served two terms on the USPTO Public Patent Advisory Committee (PPAC), and served as Chairman, E-government Subcommittee advising on Patent Office IT infrastructure and software tools. He is an immediate past member of the Board of Directors, Intellectual Property Owners Association, and a member of the Licensing Executives Society and Patent Information Users Group. Mr. Gibbs authored the corporate patent strategy book, Essentials of Patents (Wiley), PatentWiter (Sq. One), and more than 100 patent quality and IP management articles.
[back to top]
Robert B. Goldman
Robert B. Goldman, Principal, assists clients in developing and implementing strategies for managing and realizing value from their intellectual property portfolios. He has consulted on numerous engagements involving the valuation of intellectual property and intangible assets for licensing and sale transactions, mergers and acquisitions, corporate spin-outs, corporate restructuring, and other purposes. Mr. Goldman is experienced in performing IP analytics research to assist clients in making informed IP-related decisions in variety of contexts such as M&A due diligence, transaction target identification and prioritization, and risk assessment. His litigation experience includes the determination of reasonable royalties and lost profits in patent infringement matters, valuation/damages in technology license disputes, and damages in trade secret misappropriation matters. Mr. Goldman is active in the Licensing Executives Society (LES) as a frequent speaker and instructor on IP Valuation and IP Intelligence.
[back to top]
Mark Gordon
Mark Gordon is a cofounder and director of Vantage Partners and is a Senior Advisor to the Harvard Negotiation Project at Harvard Law School. As an expert in negotiation and relationship management, he has worked with leading companies across a range of industries including financial services, entertainment, healthcare, information technology, manufacturing, and telecommunications. He works with clients to help develop and implement strategies for maximizing the value from both intra-organizational collaboration and relationships with alliance partners, customers, and suppliers.
Mark has worked on every continent except for Antarctica, and much of his work focuses on enhancing cross-cultural communication and relationship management. His work has ranged from advising clients on significant strategic negotiations to helping clients systematize negotiation and relationship management as key business processes, structure and launch new alliances, and transform their approaches to managing key suppliers as business partners rather than simply as vendors.
In addition to his work at Vantage Partners, Mark is a co-founder and has been Chairman of Conflict Management Group, a 501(c)(3) non-profit organization focused on disputes of international public concern, and serves on the Board of Mercy Corps after CMG 's merger with Mercy Corps. In his more than twenty years of experience in the public sector, Mark has worked with President Ortega of Nicaragua on negotiations between the Sandinistas and Contras, President Duarte of El Salvador on negotiations between the Government and the FMLN, and the PLO negotiation support group reporting to the late Yasser Arafat, Abu Masen, and Saeb Erakat, as well as Israeli negotiators from the IDF, police, foreign ministry, and prime minister 's office. In addition, he has worked with the ANC in South Africa on the constitutional negotiations led by Cyril Ramaphosa and Roelf Meyer, taught at the NATO Defense College in Rome, and conducted training for numerous foreign ministries around the world.
Prior to specializing in negotiations full-time in 1984, Mark practiced law as a corporate attorney with the firm of Cravath, Swaine & Moore in New York, worked for the U. S. State Department 's Arms Control and Disarmament Agency on U.S.-Soviet strategic arms reduction negotiations, the Democratic National Committee, Senator Hubert Humphrey, and Ralph Nader.
Mark is the co-author of Vantage 's cross-industry study, Negotiating and Managing Key Supplier Relationships. He is a frequent speaker on negotiation, alliance strategy and relationship management and has written for a variety of publications including The Harvard Communication Update. Mark has also appeared on MSNBC as a negotiation expert.
His newest book, co-authored with Danny Ertel, was released by Harvard Business School Publishing in October 2007. The book, The Point of the Deal: How to Negotiate When Yes Is Not Enough, focuses on suggestions for practitioners, managers, and organizations on how to negotiate when the value of the deal flows after the contract is signed. The Point of the Deal won the Outstanding Book of the Year Award from CPR for 2007.
Mark has a J.D. from Harvard Law School and an A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University.
[back to top]
John P. Gourary
John P. Gourary, co-head of Finance at Covington & Burling LLP, has more than 25 years of experience in structured finance and other asset-based transactions, as well as in mergers and acquisitions and venture capital transactions. He has handled transactions in these areas for, among others, Abbey National, Abbott Laboratories, Charlesbank Capital Partners, Emory University, GE Capital, Genworth, LIN Television, Kerr-McGee, Microsoft, Northwestern University, Resource America, Tronox, UBS, University of Rochester and Zurich Financial Services.
Mr. Gourary 's practice has recently centered on innovative financings of unusual asset classes, including, in particular, monetizations of pharmaceutical royalty streams. He advised Northwestern University on the sale of a portion of its worldwide royalty interest in Lyrica for $700 million, the largest monetization ever of a royalty stream for a pharmaceutical product. Mr. Gourary also advised Emory University on its ground-breaking monetization of the royalty rights associated with Emtriva for $540 million, recognized by Investment Dealers ' Digest as the 2005 Healthcare Deal of the Year, and helped Centre Solutions, a member of the Zurich Financial Services Group, develop and structure the first pharmaceutical royalty securitization, a $130 million senior/subordinated financing, on behalf of a major university, of the rights associated with the intellectual property at the core of a leading pharmaceutical product.
[back to top]
Daniel Grau
Daniel Grau is CEO and Vice-Chairman of Cortria Corporation, a clinical stage pharmaceutical company focused on creating safe and well-tolerated medicines for the treatment of cardiovascular disease. Mr. Grau is also a member of the Product Advisory Board of Concert Pharmaceuticals and the Advisory Board of Hygeia Therapeutics. Prior to his appointment as CEO of Cortria, Mr. Grau was Chief Operating Officer of CombinatoRx (NASDAQ: CRXX) and a business consultant to Pharmacia Corporation (now Pfizer). Mr. Grau earned his B.A. with High Honors in English Literature from Davidson College, and his M.A., M.A.R., and M.Phil. degrees in Philosophy & Religious Studies from Yale University, where he held an Andrew J. Mellon Fellowship in the Humanities.
[back to top]
Leon B. Greenfield
Leon B. Greenfield is a partner of the firm's Regulatory and Government Affairs Department, and a member of the Antitrust and Competition and Defense and National Security Practice Groups. He joined the firm in 1990. He has an exceptionally wide breadth of experience representing clients in complex antitrust-related matters. He has secured antitrust clearance for major acquisitions, litigated cases in federal and state court and counseled clients on many types of antitrust issues. Mr. Greenfield also has broad experience in matters outside the antitrust area, including securities regulatory matters and litigation and complex business litigation.
Mr. Greenfield's practice includes obtaining merger clearance for transactions in a diverse range of industries, including defense and aerospace, software products, scientific equipment, agricultural and other chemicals, entertainment, professional services, airlines and financial services. Many of those transactions have required regulatory approval both in the United States and other countries.
Mr. Greenfield has also handled many civil non-merger competition matters, both in the United States and the European Union, and regularly counsels clients on antitrust matters. He has represented clients in a variety of securities, regulatory and litigation matters and has been involved in many litigation and major internal investigations in the defense and aerospace, securities and corporate governance areas.
[back to top]
Jon Grossman
Jon Grossman is a partner in the Intellectual Property
Practice. Mr. Grossman practices in the areas of patent law,
copyright law, and licensing work with a specialization in
issues concerning computer software. He has significant
commercial licensing experience encompassing all aspects
of contracting, including inbound and outbound licenses,
development agreements, Internet contracting, and
copyright related agreements. Mr. Grossman also provides
clients a full range of IP counseling with a business focus
in the areas of strategic acquisitions, outsourcing, and joint
ventures and enforcement. Additionally, he works closely
with clients in obtaining financing from venture capitalists.
[back to top]
Robert R. Gruetzmacher, Ph.D.
Dr. Gruetzmacher is the Director of Technology Commercialization in DuPont's Center for Collaborative Research and Education. During his career with DuPont, his responsibilities have included research, development, manufacturing, and marketing in the photopolymer imaging products and medical diagnostic businesses. He managed DuPont’s infectious disease diagnostics research group in Boston, co-managed a food quality assurance business venture, and helped lead development of DuPont's technology transfer group and intellectual assets business.
In his current role in the Center for Collaborative Research and Education he manages the unrestricted grants program, helps lead DuPont’s efforts to find appropriate university partners for sponsored and collaborative research, negotiates agreements and seeks new business opportunities with the academic setting, and advises company-wide on licensing-related matters. Most recently, he has been asked to take a lead in facilitating corporate-wide implementation of an “open innovation” R&D model.
Dr. Gruetzmacher holds a Ph.D. from Case Western Reserve University, and was the recipient of a National Institutes of Health Postdoctoral Fellowship. He has served as a trustee of the Licensing Executives Society and participates in several international forums dealing with topics such as university/company transactions, knowledge management, and the management and valuation of intellectual assets. He has authored publications and is invited frequently to gives talks on these topics. He is a member of the Licensing Executives Society, the American Chemical Society, the Association of University Technology Managers, and the American Association for the Advancement of Science. He is on the industrial advisory boards of the Larta Institute in Los Angeles, the Larta/USDA Commercialization Assistance Program and the Department of Macromolecular Science and Engineering at Case Western Reserve University.
Dr. Gruetzmacher is a Certified Licensing Professional and is the owner and president of the technology transfer consulting firm, TechIAConnect and Associates. He is also an associate of the consulting and business development services firm, IntellectualAssets, Inc.
[back to top]
David Gulley
David Gulley, PhD, is Associate Vice President for Technology and Economic Development for the University of Illinois campuses (www.uillinois.edu) and Assistant Vice Chancellor for Research at the UI Chicago campus. In these roles he provides leadership in technology-based economic development which includes academic-industry interactions and technology commercialization. David has over 20 years of experience in academic-industry interactions, especially in technology transfer with life science and biopharma industries. Gulley holds an MA from Virginia Tech and a BA and PhD from Southern Illinois University.
[back to top]
|
